TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics
TCON Price/Volume Stats
| Current price | $0.18 | 52-week high | $2.19 |
| Prev. close | $0.18 | 52-week low | $0.17 |
| Day low | $0.18 | Volume | 2,504 |
| Day high | $0.18 | Avg. volume | 286,475 |
| 50-day MA | $0.26 | Dividend yield | N/A |
| 200-day MA | $0.96 | Market Cap | 5.65M |
TCON Stock Price Chart Interactive Chart >
TRACON Pharmaceuticals, Inc. (TCON) Company Bio
Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.
Latest TCON News From Around the Web
Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as PlannedFull ENVASARC accrual expected in Q4 and final data expected in mid-2024SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses o |
TRACON Pharmaceuticals Announces Participation at Upcoming Investor ConferencesSAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overvi |
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot PoleThere are some solid biotech stocks on the market. |
Q2 2023 TRACON Pharmaceuticals Inc Earnings CallQ2 2023 TRACON Pharmaceuticals Inc Earnings Call |
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateSAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time |
TCON Price Returns
| 1-mo | -31.30% |
| 3-mo | N/A |
| 6-mo | -90.72% |
| 1-year | -89.22% |
| 3-year | -96.13% |
| 5-year | -99.12% |
| YTD | -87.92% |
| 2022 | -46.21% |
| 2021 | -76.32% |
| 2020 | 400.00% |
| 2019 | -62.86% |
| 2018 | -81.19% |
Loading social stream, please wait...